Dr. Naval Daver is a Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and is an internationally renowned AML clinical investigator focused on molecularly targeted and immune-based therapies in AML. He currently serves as the principal investigator on over 25 ongoing national and international clinical trials. He co-leads the AML program at MDACC that has led many of the recent FDA drug approvals in AML. He has published more than 600 manuscripts and is an editor on numerous high impact journals.